Yumanity Therapeutics, Inc. (YMTX) Income Statement Analysis

See more : Arrow Minerals Limited (AMD.AX) Income Statement Analysis – Financial Results

Complete financial analysis of Yumanity Therapeutics, Inc. (YMTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Yumanity Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Yumanity Therapeutics, Inc. (YMTX)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.yumanity.com

About Yumanity Therapeutics, Inc.

Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Unable to fetch income statement for: YMTX

Why Are Chinese Stocks Up Today?

December 5, 2022investorplace.com

Chinese stocks are rallying on Monday as investors get more hopeful news of the country loosening its Covid-19 restrictions. Over the weekend, China reportedly let go of some of its restrictions on certain cities affected by the pandemic.

Why Is Yumanity Therapeutics (YMTX) Stock Up Today?

December 5, 2022investorplace.com

Yumanity Therapeutics (NASDAQ: YMTX ) stock is rocketing higher on Monday after the clinical-stage biopharmaceutical company announced a special dividend. According to a press release from the company, this special dividend will range in price from $1.34 to $1.43 per...

Best Penny Stocks to Buy That Exploded Today? 3 to Watch

June 6, 2022pennystocks.com

Check these penny stocks out for your watchlist right now The post Best Penny Stocks to Buy That Exploded Today? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Why Is Yumanity Therapeutics (YMTX) Stock Up 50% Today?

June 6, 2022investorplace.com

Yumanity Therapeutics (YMTX) stock is rocketing higher on Monday after announcing two definitive agreements. including a merger.

Yumanity Therapeutics Shares Trading Higher Today - Read Here Why

June 6, 2022benzinga.com

Yumanity Therapeutics Inc (NASDAQ: YMTX) has agreed to sell its lead clinical-stage product candidate, YTX-7739, and discovery-stage neuroscience candidates to Janssen Pharmaceutica NV, a unit of Johnson & Johnson (NYSE: JNJ) for $26 million. Yumanity plans to.

Yumanity Therapeutics (YMTX) Reports Q1 Loss, Misses Revenue Estimates

May 12, 2022zacks.com

Yumanity (YMTX) delivered earnings and revenue surprises of -21.57% and 31.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Yumanity Therapeutics to Present at the H.C. Wainwright BioConnect Conference

January 4, 2022globenewswire.com

BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer,...

Yumanity Therapeutics to Present at Multiple Upcoming November Investor Conferences

November 16, 2021globenewswire.com

BOSTON, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer,...

Yumanity Therapeutics Stock Plunges After Parkinson's Trial Data

November 10, 2021benzinga.com

Yumanity Therapeutics Inc (NASDAQ: YMTX) reported topline data from Phase 1b trial of its lead product candidate, YTX-7739, for mild-to-moderate Parkinson's disease. The study achieved its primary endpoints.

Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 14, 2021globenewswire.com

BOSTON, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the grant to an employee of non-statutory stock options for...

1 2

Source: https://incomestatements.info
Category: Stock Reports

Yumanity Therapeutics, Inc. (YMTX) Income Statement Analysis – Financial Results

Leave a Reply Cancel reply

Recent Posts

Categories